Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Evomela Clear all
Terminated Not applicable Interventional

Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors

NCT00966498
View directory record Official record
Conditions
High Risk Solid Tumors, Recurrent Solid Tumors
Interventions
Peripheral Blood Stem Cell Transplant
Procedure
Lead sponsor
Emory University
Other
Eligibility
Up to 35 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 26, 2026, 1:03 PM EDT
Recruiting No phase listed Observational

Umbilical Cord Blood Transplantation From Unrelated Donors

NCT03016806
View directory record Official record
Conditions
Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
Interventions
Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
Radiation · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
2 Months to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

NCT00916058
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Melphalan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00045136
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
melphalan, peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
Drug · Procedure · Radiation
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
5
States / cities
Birmingham, Alabama • Sacramento, California • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00008229
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00020501
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFIRI regimen, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, melphalan, hyperthermia treatment
Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00058292
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, Carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
17 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

NCT00003007
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interferon alfa, sargramostim, cyclophosphamide, dexamethasone, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Tennessee
Other
Eligibility
19 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
4
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
16
States / cities
Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 26, 2026, 1:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

NCT03128996
View directory record Official record
Conditions
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
RIC regimen, GVHD prophylaxis regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
4
States / cities
New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

NCT00477035
View directory record Official record
Conditions
Leukemia, Multiple Myeloma
Interventions
CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan
Drug
Lead sponsor
Sally Arai
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 26, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

NCT02790515
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions
Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide, Fludarabine, G-CSF, Melphalan, Mesna, Rituximab, Tacrolimus, Thiotepa, HPC,A Infusion, CliniMACS, Sirolimus
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

UARK 2003-33, Total Therapy III

NCT00081939
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 26, 2026, 1:03 PM EDT
Withdrawn Phase 2 Interventional

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01055301
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
21
States / cities
Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 26, 2026, 1:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Stem Cell Transplantation for Crohn's Disease

NCT00692939
View directory record Official record
Conditions
Crohn's Disease
Interventions
autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG, Melphalan, Thiotepa, Rituximab, Cyclophosphamide, G-CSF, Mesna
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
10 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 26, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

NCT04018937
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Fludarabine, Melphalan, Cyclosporine, Tacrolimus, Methotrexate
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 13 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Withdrawn Phase 2 Interventional

A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)

NCT00577668
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Velcade, Thalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Sep 26, 2026, 1:03 PM EDT
Recruiting Phase 3 Interventional

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Terminated Phase 3 Interventional Results available

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

NCT01339910
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute
Interventions
Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Busulfan and Cyclophosphamide, Cyclophosphamide and Total Body Irradiation
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • La Jolla, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 26, 2026, 1:03 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Stem Cell Transplantation for Hematological Malignancies

NCT00176839
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, AML, MDS
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

NCT05115630
View directory record Official record
Conditions
Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions
Cyclophosphamide, Mesna, Filgrastim, Melphalan, Fludarabine phosphate, Tacrolimus, Mycophenolate mofetil, Total Body Irradiation One Dose
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 26, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

NCT00943800
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
Interventions
Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG), Stem Cell Transplant, Stem Cells Collections, Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI), Fludarabine, Busulfan, and ATG
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
1 Year and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 26, 2026, 1:03 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

NCT00114101
View directory record Official record
Conditions
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
140
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 26, 2026, 1:03 PM EDT
Not listed Phase 1Phase 2 Interventional

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 26, 2026, 1:03 PM EDT